DRUG UTILIZATION PATTERN IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE INPATIENTS AT A TERTIARY CARE HOSPITAL
Keywords:Drug utilization, Chronic obstructive pulmonary disease, Bronchodilators
Objective: Drug utilization studies provide useful insights into the current prescribing practices. In view of this, the present study was designed to establish the drug utilization pattern in hospitalized chronic obstructive pulmonary disease (COPD) patients.
Methods: In this retrospective study, all patient data relevant to the study were obtained by examination of patient's medical records and hospital information system.
Results: A total of 237 patients with acute exacerbation were evaluated. The population predominantly consisted of males (92.4%) and most of the patients were in the age group of 61 to 70 y (39.7%). Cough, sputum production and dyspnea were observed in 88.2%, 80.6% and 37.6% patients, respectively. Hypertension (49.4%) was the most common co-morbidity. Candida albicans (16%) and Pseudomonas aeruginosa (4.6%) were the most common microorganisms isolated from sputum samples.
Majority of the patients were on multidrug therapy during both hospital stay (98.7%) and at the time of discharge (99.6%). During hospital stay, the most commonly prescribed drugs were ipratropium (91.6%) and levosalbutamol (88.2%); antibiotics and systemic corticosteroids were received by 96.2% and 83.1% patients, respectively. At discharge, antibiotics, inhaled corticosteroids, methyl xanthines, long acting beta-2 agonist and tiotropium were received by 94.1%, 93.7%, 92.4%, 86.1% and 56.5% patients, respectively.
Conclusion: The prescribing trend observed at our hospital appears to be in concordance with the current guidelines for the management of COPD patients.
Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2014. Accessed from: http://www.goldcopd.org/uploads/users/files/ GOLD_ Report_2014_Jan23.pdf. [Last accessed on 20 Jun 2015].
Vijayan VK. Chronic obstructive pulmonary disease. Indian J Med Res 2013;137:251-69.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73.
Miravitlles M. Prevention of exacerbations of COPD with pharmacotherapy. Eur Respir Rev 2010;19:119â€“26.
Evensen AE. Management of COPD exacerbations [published erratum appears in Am Fam Physician 2010;82:230. Am Fam Physician 2010;81:607-13.
Ali NK. Evidence-based approach to acute exacerbations of chronic obstructive pulmonary disease. Hosp Physician 2009;45:9-16, 38.
Lee D, Bergman U. Studies of drug utilization. In: Strom BL. editor. Pharmacoepidemiology. 4th ed. John Wiley and Sons; 2005. p. 401.
Veettil SK, Rajiah K, Kumar S. Study of drug utilization pattern for acute exacerbation of chronic obstructive pulmonary disease in patients attending a government hospital in Kerala, India. J Family Med Primary Care 2014;3:250-4.
Hunter MH, King DE. COPD: Management of acute exacerbations and chronic stable disease. Am Fam Physician 2001;64:603-12.
Johnson DC. Chronic candidal bronchitis: a consecutive series. Open Respir Med J 2012;6:145-9.
Martinez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008;47:1526â€“33.
Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013;14:49.